Tumors with high mutation capacity and antigenicity including tumors with high microsatellite instability (MSI), high tumor mutation load (TML), and mismatch repair deficiencies (dMMR) are also good candidates for PD-1 blockade treatment regimens [48–53]. The gene discussed is PDCD1; the disease is neoplasm.